Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

28.05 +1.01 (+3.74%)
Streaming Delayed Price Updated: 11:06 AM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
23 24 Next >
Market Whales and Their Recent Bets on VKTX Options
Via Benzinga
If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today
What would a $100 investment in Viking Therapeutics back in 2022 be worth today? Prepare to be surprised. 
Via The Motley Fool
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
Investors should take a close look at these biotech stocks as they position themselves to provide high returns. 
Via InvestorPlace
Where Will Viking Therapeutics Be in 5 Years?
Could Viking Therapeutics become a big player in the GLP-1 drug market? 
Via The Motley Fool
2 Stocks That Could 10x by 2035
These stocks are very promising, but it's important to consider the downside, too. 
Via The Motley Fool
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
Discover three top Nasdaq stocks to buy. Learn about these investment opportunities and why they’re worth your attention. 
Via InvestorPlace
Smart Money Is Betting Big In VKTX Options
Via Benzinga
Is Viking Therapeutics Stock a Buy?
The stock could have room to soar higher if VK2735 obtains approval from regulators. 
Via The Motley Fool
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Is It Too Late to Buy Viking Therapeutics Stock?
This rising star probably won't burn out soon. 
Via The Motley Fool
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
3 Growth Stocks That Could Be Millionaire-Makers: May Edition
Investors wanting to get rich should consider a long-term holding in these stocks, each of which has risen exponentially in the last year. 
Via InvestorPlace
Wall Street Favorites: 3 Russell 2000 Stocks With Strong Buy Ratings for May 2024
Consider following the recommendations of analysts and buy these small but mighty companies whose stocks are rising. 
Via InvestorPlace
3 Monster Stocks in the Making You Can Buy Right Now
These stocks might not be small for too much longer. 
Via The Motley Fool
How Is The Market Feeling About Viking Therapeutics?
Via Benzinga
Viking Therapeutics's Options Frenzy: What You Need to Know
Via Benzinga
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason. 
Via InvestorPlace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper highlights five stocks weekly that are seeing increased interest from readers. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. 
Via InvestorPlace
Tiny but Mighty: 3 Small-Cap Stocks Crushing the Russell 2000
Top small-cap stocks to buy Viking Therapeutics, Celsius and Hippo make waves in the weight loss, energy drink, and insurance tech sectors. 
Via InvestorPlace
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet. 
Via InvestorPlace
How Viking Therapeutics Stock Could 30x
This mid-cap biopharma may one day be a titan of the industry. 
Via The Motley Fool
Is Viking Therapeutics the Best Biotech Stock for You?
With good mid-stage results and plenty of cash, Viking could be a winner. 
Via The Motley Fool
The 3 Best Russell 2000 Stocks to Buy in May 2024
If you are looking for investments that will deliver high returns, these are the best Russell 2000 stocks to buy for your portfolio. 
Via InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs 
Via MarketBeat
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
The anti-obesity medication stock is way up, and there could be more fuel in the tank. 
Via The Motley Fool
What Is the Best Weight Loss Stock to Buy Now? Our Top 3 Picks
Data indicates that many more Americans have become aware of the dangers of obesity. Here are the best weight loss stocks to buy now. 
Via InvestorPlace
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.